BioCentury
ARTICLE | Clinical News

IV Brinavess vernakalant: Clinical trial data

October 7, 2013 7:00 AM UTC

An open-label study in 150 patients with symptomatic, recent onset AF without structural heart disease or hemodynamic instability showed that patients treated with IV Brinavess achieved conversion to normal sinus rhythm in a median time of 12 minutes vs. 151 minutes for propafenone and 162 minutes for flecainide (p<0.01 for both). Brinavess also significantly reduced median hospital length of stay (243 minutes) vs. both propafenone (422 minutes) and flecainide (410 minutes) (p<0.01). Patients received Brinavess at an initial dose of 3 mg/kg for 10 minutes and an additional 2 mg/kg dose if their AF had not resolved within 15 minutes, a single 600 mg dose of oral propafenone or a single 300 mg dose of oral flecainide. Data were published in the Journal of Atrial Fibrillation. The drug is approved in the EU for rapid conversion of recent onset AF to sinus rhythm for non-surgery, adult patients with AF of >=7 days and for post-cardiac surgery, adult patients with AF of >=3 days. ...